AZBio Fast Lane Award Winner and Leading Social Health Company for Women Partners With the Leader in Health Video to Expand Reach for Its Women’s Health Video Continue reading
Category Archives: BioScience
From Discovery to Patient: The Journey of a New Drug
The development of a new drug is a long, complicated process involving up to 15 years of research and, in many cases, hundreds of millions of dollars. There are two distinct processes that every drug must go through before reaching the general patient population and treating a specific disease – Drug Discovery and Drug Development.Continue reading
2011 Fast Lane Honoree Algae Bio expands production facilities
In a region that is rapidly becoming known as a mecca for the natural resource industry with potash, solar and wind energy, another resource, algae, is now gaining notice. Six years ago Andrew Ayers bought 70 acres of land in an area east of Holbrook known as Adamana, believing it held something that to him was more precious than gold. In the vast open desert of northeastern Arizona Ayers discovered that beneath the surface lay pure salt water, and that salt water is ideal for Ayers’ research in macro algae.Continue reading
NAU and Flagship Biosciences Partnership Featured Inside NAU
Partnership with biotech firm magnifies student skillsContinue reading
‘Dream Team’ stands up to melanoma cancer
December 14, 2011:
Joe Caspermeyer, Biodesign Institute via http://asunews.asu.edu/20111214_melanomadreamteam
ASU’s Deirdre Meldrum and Joshua LaBaer, of the Biodesign Institute, have been named to the new Melanoma Dream Team created by Stand Up to Cancer, the Melanoma Research Alliance and the American Association for Cancer Research (AACR). The collaborative Dream Team project, involving scientists from top research institutions across the country, is focused on developing targeted, personalized therapies for a subtype of skin cancer that is difficult to treat. The Translational Genomics Research Institute (TGen) and the Barbara Ann Karmanos Cancer Institute will lead the $6 million national and international study.Continue reading
City of Maricopa sheds light on the future economy
The City of Maricopa’s 5th Annual Economic Development Summit sheds light on new developments and the future economy.
On Thursday December 8, 2011, the City of Maricopa held its 5th Annual Economic Development Summit. Over 100 attendees were present, representating the development, land investment, business, and real estate sectors as well as local stakeholder group.Continue reading
Peoria Mayor Welcomes the addition of new Medical Device and Bioscience Incubator
As seen in the Arizona Republic on 11/18/2011
Peoria will soon play host to bioscience startups, with the lofty long-term goal of becoming a bioscience hub focused on medical devices that would bring high-paying jobs to the city.
The Peoria City Council on Tuesday night unanimously approved a partnership with BioAccel, a Phoenix non-profit that mentors startups, as well as Plaza Companies of Peoria, which would host the Peoria Incucelerator. The name comes from the combination of incubator and accelerator.Continue reading
Supporting Innovation– Your Opportunity to Send a Message to Congress on the TDP
The Bioscience community is reaching our to leaders in Washington to support the Therapeutic Discovery Project Tax Credit program (TDP) (I.R.C. §48D) and its impact on bioscience and U.S. innovation. The letter below has been signed by BIO, AZBio and bioscience companies and organizations across the country. Continue reading
U of A researchers developing a sweet energy solution
Known as the sugarcane of the desert, sweet sorghum could be a sustainable and ecological future biofuel crop for Arizona.Continue reading
NEW NCI SBIR Phase II Bridge Award: Bridging the Valley of Death
The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs has announced the FY2012 SBIR Phase II Bridge Award, designed to support the next stage of development for previously funded NIH-wide SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, diagnostics and prognostics. The NCI intends to commit up to $10 million in fiscal year 2012 to fund up to ten new awards.Continue reading